Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis

Respiratory Medicine

Volumn 100, Issue 6, 2006, Pages 1079-1087

  Dlugovitzky, Diana ^a   Fiorenza, Gladys ^a   Farroni, Miguel ^b   Bogue, Christine ^b   Stanford, Cynthia ^c   Stanford, John ^c  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Hospital I Carrasco   (Argentina)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Mycobacterium vaccae; Three dose immunotherapy; Tuberculosis

Indexed keywords

CD11B ANTIGEN; ETHAMBUTOL; IMMUNOMODULATING AGENT; INTERLEUKIN 4; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; SRL 172; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARGENTINA; ARTICLE; BACTERIAL IMMUNITY; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY BURST; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SPUTUM ANALYSIS; TH1 CELL; TH2 CELL; THORAX RADIOGRAPHY; TREATMENT FAILURE;

ADULT; AGED; ANTITUBERCULAR AGENTS; BACTERIAL VACCINES; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VACCINES, ATTENUATED;

EID: 33646030263     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.09.026     Document Type: Article

References (21)

1. Stanford J., Stanford C., and Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Frontiers Biosci 9 (2004) 1701-1719
2. Rook G.A.W., Hernandez-Pando R., Dheda K., and Seah G.T. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 (2004) 483-488
3. Onyebujoh P.C., Abdulmumini T., Robinson S., et al. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 89 (1995) 199-207
4. Corlan E., Marica C., Macavei C., et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly diagnosed pulmonary disease. Respir Med 91 (1997) 13-19
5. Dlugovitzky D., Bottasso O., Dominino J.C., et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med 93 (1999) 557-562
6. Luo Y. National Cooperation Group on clinical study of Mycobacterium vaccae vaccine. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 24 (2001) 43-47
7. Corlan E., Marica C., Macavei C., et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 91 (1997) 21-29
8. Etemadi A., Farid R., and Stanford J.L. Immunotherapy for drug-resistant tuberculosis (letter). Lancet 340 (1992) 360-361
9. Luo Y., Lu S., and Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 23 (2000) 85-88
10. Zheng X.M., Li S.M., and Xing B.C. Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao (2004) 578
11. Stanford J.L., Stanford C.A., Grange J.M., et al. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?. Respir Med 95 (2001) 444-447
12. Stanford J.L., Onyebujoh P.C., Rook G.A., et al. Old plague, new plague, and a treatment for both?. AIDS 7 (1993) 1275-1277
13. Mwinga A., Nunn A., Ngwira B., et al., LUSKAR collaboration. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360 (2002) 1050-1055
14. Pedrosa J., Saunders B.M., Appelbert F., et al. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 68 (2000) 577-583
15. Adams L.B., Dinauer M.C., Morgenstern D.E., and krahenbuhl J.L. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tuberculosis Lung Dis 78 (1997) 237-246
16. Bogdan C., Röllinghoff M., and Diefengach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 12 (2000) 64-76
17. Sredni-Kenigsbuch D., Kambayashi T., and Strassmann G. Neutrophils augment the release of TNFa from LPS-stimulated macrophages via hydrogen peroxide. Immunol Lett 71 (2000) 97-102
18. Shalekoff S., Tiemessen C.T., Gray C.M., et al. Depressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus Type 1 infection. Clin Diagn Lab Immunol 5 (1998) 41-44
19. Dlugovitzky D., Bay M.L., Rateni L., et al. In vitro synthesis of interferom-γ, transforming growth factor-β, interleukin 1b by peripheral blood mononuclear cells from tuberculosis patients: relationship with the severity of pulmonary involvement. Scand J Immunol 49 (1999) 210-217
20. Aleman M., Garcia A., Saab M.A., et al. Mycobacterium tuberculosis-induced activation accelerates apoptosis in peripheral blood neutrophils from patients with active tuberculosis. Am J Respir Cell Mol Biol 27 (2002) 583-592
21. Do Hoai Thanh. Combination of immunotherapy with Mycobacterium vaccae in new smear-positive TB patients in districts in Hanoi and Hatay Province, Vietnam. The International Journal of Tuberculosis and Lung Disease 2005; 9: S162 (Poster PS-1013-21, presented in the Bacteriology/Immunology section at the 36th World conference on lung health of the International Union Against Tuberculosis and Lung Disease, Paris, France 18th-22nd October 2005).